SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the community anticipates potential bullish catalysts, including a possible trade deal and upcoming rate cuts, while also digesting news of institutional adoption. Traders are actively discussing technical patterns, potential price movements, and the impact of market manipulation. The conversation also includes the broader implications for Ethereum's ecosystem and Web3 growth.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recently announced oversubscribed $150 million registered direct offering and a $5 million production order, signaling a shift from R&D to manufacturing. The community is discussing the potential impact of these developments, particularly the Luxshare-Meta connection and the possibility of further purchase orders. Bullish sentiment is fueled by comparisons to previous tech breakouts and the potential for POET's optical interposer technology to revolutionize AI data transmission.

WorldFinancial

WorldFinancial ($WLFI) is trending as the community anticipates upcoming news and potential integration with financial services. Bullish sentiment is fueled by discussions of technical patterns like cup and handle formations, as well as speculation around adoption by financial institutions and governments. Community members are actively discussing potential price surges and the broader implications for the altcoin market, with some drawing parallels to other meme coins.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending due to Ethereum's recent price movements, with community members closely watching its correlation and potential impact on BMNR's price; discussions include short positions, possible price targets, and the influence of figures like Tom Lee. The broader context involves speculation around ETH accumulation and potential market manipulation.

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is gaining attention, with community members highlighting its potential for a breakout and strong chart setup, particularly within the Phantom Wallet ecosystem. Talk centers around the token's steady performance amid market hesitation and its potential for significant upward momentum. The community emphasizes its growing momentum and accessible entry point.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is trending as the community rallies around its core principle: "We're All Gonna Make It". Discussions highlight the project's resilience, strong community, and potential within the Solana ecosystem, with many believing it's poised for significant growth. Some users are suggesting that WAGMI will follow a similar trajectory as other popular meme coins.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind ($MNKD) is trending amid community discussion around a recent Motley Fool interview with the CEO and its potential implications.  Shareholders are debating the CEO's performance and potential future catalysts like pipeline drugs and partnership opportunities.  The stock's valuation and potential for a merger are also hot topics.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending following Novartis' ($NVS) acquisition agreement, which sent the stock soaring. The community is buzzing about the significant premium offered and potential windfalls for option holders and biotech investors. Some speculate about other potential buyout targets in the sector, while others discuss the deal's implications for Avidity's pipeline and spun-off cardiology programs.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

$QKITTY is trending as the community discusses its trading bot, which some claim generates daily interest. Some users express excitement for upcoming updates, while others share concerns, using the $BROKE tag. The coin is built on Solana, and there are mentions of potential integration with decentralized exchanges.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to optimism surrounding potential US-China trade deal developments, with discussions covering key trade issues and export controls. Community members are weighing the impact of this framework on the market, especially on futures, with many anticipating a bullish open. Concerns remain about whether this optimism is justified, the details of the deal, and its long-term impact.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice

Does Roivant Sciences Ltd. (ROIV) have what it takes to be a top stock pick for momentum investors? Let's find out.

Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?

Montes Archimedes Acquisition (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shares of Roivant (ROIV) jumped 9% on Wednesday after the company, along with Priovant Therapeutics, announced positive results from a late-stage trial evaluating Brepocitinib in dermatomyositis.Dermatomyositis is a multi-organ idiopathic inflammatory condition that affects approximately 50,000 adults in the U.S. and is characterized by debilitating muscle weakness and skin lesions. No targeted therapies are approved for the condition, and a majority of patients are treated with high-dose oral steroids.Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, including measurements of skin disease, muscle disease, steroid-sparing effect, and rapidity of onset, the company said.On Stocktwits, retail sentiment around ROIV stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:619/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_2_05_09_PM_png_94ffd6f84d.webp" alt="ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="619" height="61"><figcaption>ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism that the stock would rally further to $17.<stembedurl>https://stocktwits.com/StockBraker/message/628947861</stembedurl>Another user also cheered the stock’s rally over the past few weeks.<stembedurl>https://stocktwits.com/bbbloo/message/628950392</stembedurl>The company stated that 30mg of Brepocitinib achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo. It added that more than two-thirds of patients receiving the Brepocitinib 30 mg dose experienced at least a moderate response, with a TIS equal to or greater than 40, and nearly half experienced a major response, with a TIS equal to or exceeding 60.Furthermore, 42% of Brepocitinib 30 mg patients were able to discontinue steroids altogether, compared to 23% for the placebo, while 62% achieved a steroid dose of 2.5 mg or less per day. The safety profile observed in the study was consistent with that of previous trials, the company stated.The company plans to file for approval of the drug with the U.S. Food and Drug Administration for the treatment of dermatomyositis in the first half of 2026.ROIV stock is up 31% this year and approximately 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gm-in-talks-to-renew-jv-with-chinas-saic-report/chDGDTkRd6t">GM In Talks To Renew JV With China’s SAIC: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Roivant Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said. 

Equity

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said. 


Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +21.74% and -71.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates

Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates

Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Roivant Sciences Ltd

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

ROIV
Roivant Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ROIV News

ROIVRoivant Sciences Ltd